BRN (ASX) RT presentation, 12 Oct 2021

Originally posted by Fact Finder: ↑

Of course you will be because you have no idea about how the LDA Capital agreement works.

Probably pointless to explain but here goes:

1. LDA Capital are not holding any Brainchip shares from this present extension of the agreement.

2. Before 28.2.22 Brainchip will issue sufficient shares to LDA Capital to sell on market to gross $5.3 million dollars. Brainchip will receive 90% of the $5.3 million and LDA Capital will receive 10% of the $5.3 million. Any shares that do not need to be sold will be either held in trust by LDA Capital for the next agreed put option exercise or returned to Brainchip (at Brainchip's discretion) as they have remained throughout this process Brainchip shares not LDA Capitals

3. Before 31.12.22 Brainchip will issue sufficient shares to LDA Capital to sell on market to gross $15 million dollars. Brainchip will receive 91.5% of the $15 million and LDA Capital will receive 8.5% of the $15 million. Any shares that do not need to be sold will be either held in trust by LDA Capital for the next agreed put option exercise or they will be returned to Brainchip (at Brainchip's discretion) as they have remained throughout this process Brainchip shares not LDA Capitals

4. Before 31.12.23 Brainchip will issue sufficient shares to LDA Capital to sell on market to gross $15 million dollars. Brainchip will receive 91.5% of the $15 million and LDA Capital will receive 8.5% of the $15 million. Any shares that do not need to be sold will be either held in trust by LDA Capital for the next agreed put option exercise or they will be returned to Brainchip (at Brainchip's discretion) as they have remained throughout this process Brainchip shares not LDA Capitals

5. The above are the minimum calls under the agreement which must be made by Brainchip under the put option. They total $35 million dollars. The total extended agreement is $65 million which means that should Brainchip wish to do so it can call via a put option during the agreement period up to a further $30 million on the same terms as set out above in 3. and or 4.

6. Any or all of these 2. 3. 4. 5. calls on the put option will be notified at the time via the ASX. The higher the market price of Brainchip shares the less shares they need to issue to LDA Capital. In simple terms if the price is $1.00 per share they will only need to issue 5.3 million shares to achieve $5.3 million.

As I stated yesterday LDA Capital unlike the first time around did not get any up front shares either as a fee in lieu of cash or as options so they have no shares to sell other than the above which remain Brainchip shares throughout the process. Unless LDA Capital now come on market and buy more Brainchip shares which is not their business model they have no shares to sell on market. The price of Brainchip shares is irrelevant to LDA Capital as they get the same money regardless under the deal it is in effect a fixed price agreement from their perspective.

On any view LDA Capital have significantly discounted the present deal to Brainchip over the original deal to get Brainchip's further business.

I invite you to copy my post and send it to Tony Dawe at Brainchip and ask him if what I have stated is correct.

My opinion only DYOR
FF

AKIDA BALLISTA

Expand

Not bad FF,

Query on point 5 though. I think you need to include the earlier sums from the original agreement as well as the $5.3M you highlighted. Should read something like this.

Original agreement: $29M available with a minimum $10M draw down.
1st Amendment : $45M available with a minimum $20M draw down.
2nd Amendment : $65M available with a minimum $50M draw down.

Yes, LDA have offered a better rate but our obligation is increasing as the funding gets higher. Regardless of how much revenue comes in and how strong the balance sheet is, BRN must make the calls you outlined.

No.	Vol.	Price($)
54	1621358	19.5¢

No.

Vol.

Price($)

1621358

19.5¢

Price($)	Vol.	No.
20.0¢	492126	33

Price($)

Vol.

No.

20.0¢

492126

No.	Vol.	Price($)
55	1628219	0.195
71	2050085	0.190
28	1181041	0.185
53	1310948	0.180
12	522850	0.175

No.

Vol.

Price($)

1628219

0.195

2050085

0.190

1181041

0.185

1310948

0.180

522850

0.175

Price($)	Vol.	No.
0.200	372248	27
0.205	1271867	34
0.210	1465209	19
0.215	608859	16
0.220	679186	23

Price($)

Vol.

No.

0.200

372248

0.205

1271867

0.210

1465209

0.215

608859

0.220

679186

(20min delay)
Last 20.0¢		Change -0.005(2.44%)		Mkt cap ! $366.5M

Open	High	Low	Value	Volume
20.0¢	20.5¢	19.8¢	$429.6K	2.149M

Not bad FF,Query on point 5 though. I think you need to include...

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Not bad FF,Query on point 5 though. I think you need to include...

Top Stories

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News